230 filings
Page 5 of 12
424B5
pnll4
22 Sep 20
Prospectus supplement for primary offering
4:09pm
EFFECT
zlt9vd1k
21 Sep 20
Notice of effectiveness
3:26pm
CORRESP
i1vtwhm2c069ge18 j0h
16 Sep 20
Correspondence with SEC
12:00am
UPLOAD
u71hem 8fnhg0t2i
15 Sep 20
Letter from SEC
12:00am
F-3
n5u9w2
11 Sep 20
Shelf registration (foreign)
4:04pm
6-K
x5m7w3w4f4dkmlo9dul0
6 Aug 20
Current report (foreign)
4:30pm
6-K
oz50yxvekl
20 Jul 20
Current report (foreign)
5:01pm
6-K
as0524c
14 Jul 20
ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures
5:21pm
6-K
ncfo713l2wm
24 Jun 20
Current report (foreign)
4:10pm
6-K
2sko0 08tu5
26 May 20
ProQR Announces Annual Meeting of Shareholders
4:08pm
6-K
nqq nalqg
7 May 20
Current report (foreign)
7:31am
424B5
2r7 9ppvmiy
31 Mar 20
Prospectus supplement for primary offering
4:49pm
6-K
6092509
31 Mar 20
ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
7:11am
6-K
mcas 0rmrxetku
26 Feb 20
Current report (foreign)
7:52am
6-K
04qz8rl3gcrzvbqass3
30 Jan 20
ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a
9:12am
6-K
qmxu1a szjfc9iuxs
11 Dec 19
ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
8:46am
6-K
rknhv5f42ad8t ua6i6
21 Nov 19
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
4:09pm
6-K
mkmx1sx
12 Nov 19
PROQR THERAPEUTICSÂ N.V. Index to Unaudited Condensed Consolidated Financial Statements
4:03pm
6-K
u09om qbgqztxnx15
17 Oct 19
ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
4:26pm